Observational analysis showed sustained disease control in C57BL/6 mice with autoimmune uveitis, highlighting the efficacy of targeted immunomodulation.
Key Points
Mice receiving the treatment maintained disease control for 28 weeks, showing reduced ocular inflammation and less retinal damage on OCT.
Flow cytometry indicated decreased immune cell infiltration in treated mice compared to controls, and transcriptomic analysis revealed notable gene expression changes.
This approach employed αCD4 antibody and retinal antigen injections to introduce retinal antigen-specific regulatory T cells (Tregs) effectively suppressing inflammation.
Long-term treatment may support ongoing management strategies for autoimmune uveitis with potential clinical applications.